FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

7 results

jakafi
(ruxolitinib)
Incyte Corporation
Usage: Jakafi is indicated for treating intermediate or high-risk myelofibrosis, polycythemia vera in adults intolerant to hydroxyurea, and steroid-refractory acute and chronic graft-versus-host disease in patients aged 12 and older who have not responded to prior systemic therapies.
monjuvi
(Tafasitamab-Cxix)
Incyte Corporation
monjuvi - tafasitamab - cxix injection, powder, lyophilized, for solution
(Tafasitamab-Cxix)
Incyte Corporation
niktimvo
(axatilimab-csfr)
Incyte Corporation
Usage: NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, following the failure of at least two prior lines of systemic therapy.
opzelura
(ruxolitinib)
Incyte Corporation
Usage: OPZELURA is indicated for the topical short-term treatment of mild to moderate atopic dermatitis in patients 12 years and older, and for nonsegmental vitiligo in adults and pediatric patients. It should not be used in combination with other JAK inhibitors or potent immunosuppressants.
pemazyre
(pemigatinib)
Incyte Corporation
Usage: PEMAZYRE is indicated for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, and for adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
zynyz
(retifanlimab-dlwr)
Incyte Corporation
Usage: ZYNYZ is indicated for treating adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Its approval is based on tumor response and duration, with ongoing validation of clinical benefit required from confirmatory trials.

Incyte Corporation drugs

jakafi

monjuvi

monjuvi - tafasitamab - cxix injection, powder, lyophilized, for solution

niktimvo

opzelura

pemazyre

zynyz